Market Access Across the Development Pathway includes Discovery / Pre-clinical: early unmet need mapping; target product profile (TPP) with payer-relevant claims; landscape scan (customers, competition, context). 

Phase 1–2: endpoint selection with payers/HTA in mind; PROs/HRQoL; external comparator strategy; preliminary economic model & value story; evidence gap analysis. 

Phase 3: robust comparator and subgroup strategy; utilities and resource-use capture; RWE readiness (registries/claims); pricing corridor hypotheses. 

Regulatory submission / Pre-launch: early payer dialogue; core value dossier; channel & fulfillment planning; affordability programs design. 

Launch / Post-launch: contracting & access pull-through; evidence evolution plan (RWE, VOI); label/indication sequencing.

Market Access Across the Development Pathway

Discovery / Pre-clinical

• Map unmet need and the decision context early. Identify the disease burden, current standard(s) of care, and where payers/HTA bodies consider the value gap. Early horizon scanning should explicitly anticipate how value will be assessed (clinical and economic) in priority markets.
• Shape a payer-informed Target Product Profile (TPP). Integrate market access considerations from the outset so that TPP claims and pivotal design choices reflect HTA expectations (comparators, outcomes, patient segments).
• Run an early landscape scan (customers, competition, context). Assess the competitive set, stakeholder needs (patients, clinicians, payers), and policy environment to frame an initial value proposition and research priorities. 

Phase 1–2

• Select endpoints with HTA in mind. Beyond safety/PK, anticipate decision-relevant outcomes (e.g., validated HRQoL instruments that support QALY-based assessments) and begin capturing data that will flow into cost-effectiveness models.
• Build the PRO/HRQoL plan and utilities strategy. Choose preference-based measures suitable for economic evaluation and plan analyses that can populate CUA models.
• Define comparator strategy and external evidence approach. Where head-to-head data will be limited, plan for robust indirect/mixed treatment comparisons or network meta-analysis consistent with ISPOR good practices.
• Stand up a preliminary economic model and value story. Use early data to test cost-effectiveness/budget-impact hypotheses and to spotlight evidence gaps that Phase 3 must close.
• Conduct an evidence gap analysis and seek early (parallel) scientific advice. Structured advice with regulators/HTA bodies (e.g., EMA–HTA parallel advice, PRIME, adaptive pathways) helps align on comparators, endpoints, and analyses before Phase 3. 

Phase 3

• Lock the comparator and subgroup strategy. Ensure comparators reflect real-world choices and that pre-specified subgroup analyses can inform differential value and use. Employ evidence-synthesis methods if direct head-to-head data are incomplete.
• Capture utilities and resource use prospectively. Build HRQoL and resource-use collection into trials to support CUA and BIA, and enable extrapolation in decision models.
• Ready the RWE platform. Set up registries/claims strategies to extend effectiveness/safety insights post-approval and to sustain value communication.
• Form pricing corridor hypotheses. Combine early cost-effectiveness read-outs with market constraints (e.g., external reference pricing, affordability/budget-impact limits) to define plausible price ranges. 

Regulatory submission / Pre-launch

• Engage payers early and often. Pre-submission dialogue with payers/HTA bodies and pre-approval information exchange (as allowed) align evidence packages with decision needs.
• Build the Core Value Dossier. Consolidate the clinical, economic, and humanistic evidence (HEOR and RWE) to support HTA, payer negotiations, and guideline inclusion.
• Plan channel and fulfillment. Align distribution/specialty pharmacy, hospital formulary pathways, and site-of-care logistics to remove frictions at launch.
• Design affordability and access programs. Where appropriate, prepare managed entry/patient access schemes consistent with local policy to address uncertainty and affordability. 

Launch / Post-launch

• Execute contracting and pull-through. Navigate payer tools (formulary tiering, PA/step edits, medical vs pharmacy benefit placement, rebates) and support provider uptake.
• Evolve the evidence base (including VOI). Use post-launch RWE to address remaining uncertainties; value-of-information analyses can prioritize further research that most improves decisions.
• Manage label/indication sequencing and guideline integration. Sequence indications strategically and work with guideline bodies to reflect evolving evidence. 

Stakeholders & Decision Ecosystem

External stakeholders

• Public & private payers and benefit managers: national payers, regional plans, and PBMs control coverage, utilization management, and net pricing through formulary design and contracting.
• HTA and value-assessment bodies: national/sub-national agencies (e.g., NICE, IQWiG/G-BA) and independent assessment groups (e.g., ICER in the US) synthesize clinical and economic evidence to judge value for money and added benefit.
• Regulators: FDA/MHRA/EMA (and similar) determine benefit–risk and labeling; early and parallel scientific advice can align regulatory and HTA expectations.
• Clinicians and guideline bodies: prescribers and organizations (e.g., NCCN, specialty societies) influence standard of care and payer alignment.
• Hospital systems/IDNs and P&T committees: govern formulary adoption, procurement, and in-hospital use pathways that can accelerate or constrain uptake.
• Pharmacies and distribution channels: retail, specialty, and hospital pharmacies operationalize access and utilization controls.
• Patient organizations and advocacy groups: shape evidence priorities, access programs, and policy positions; increasingly engaged in pre- and post-launch dialogue. 

Internal stakeholders

• Market Access & HEOR: lead payer strategy, economic evaluation, value communication, and HTA submissions; collaborate on endpoint selection and evidence plans.
• Medical Affairs: scientific engagement, evidence generation, and RWE, ensuring clinical credibility and post-approval data development.
• Regulatory Affairs: orchestrates submissions and compliance, and participates in scientific advice to harmonize benefit–risk with HTA needs.
• Commercial/Brand: integrates positioning, pricing strategy, and pull-through with access tactics across channels and customer types.
• Trade/Channel & Supply Chain: design distribution, site-of-care, and inventory strategies that minimize fulfillment friction at launch.
• Finance (and compliance partners): support deal modeling, rebate/contract governance, and affordability program viability.
• Policy/Government Affairs: track and shape health-policy shifts; engage appropriately with decision-makers and advocacy to align with access goals. 

Decision criteria & processes

Across markets, payer and HTA decisions weigh:

• Clinical relative value vs. relevant comparators (benefit/added benefit, safety). Robust evidence synthesis—including indirect and network meta-analysis—is often required when head-to-head trials are limited.
• Cost-effectiveness (CEA/CUA) using validated HRQoL utilities and explicit or implicit thresholds.
• Budget impact and affordability/feasibility for the health system, which drive price negotiations and access conditions.
• Equity and ethical considerations, particularly in public systems, and practical implementability (guidelines, utilization management, site-of-care).

(To be continued in next week post)